Quanterix Corp, Lexington, Mass, has announced plans to make a strategic investment in ImmunArray, Richmond, Va. Both companies are seeking to develop new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.
Quanterix and ImmunArray will work together to continue advancing research and technology in order to provide an accurate method for detecting mild to moderate traumatic brain injury. As part of the deal, ImmunArray will gain access to Quanterix’s single molecule array technology, branded as Simoa.
Quanterix will add select ImmunArray markers to its multiplex panel for the neurology research market. The additions aim to provide researchers with the ability to measure multiple proteins simultaneously, at the single molecule level, using Quanterix’s Simoa technology.
“This investment and collaboration agreement enhance our two companies’ collective ability to provide the broadest portfolio of biomarker panels to the research market utilizing highly sensitive technology,” says Donna Edmonds, chairman and CEO of ImmunArray. “As we continue to advance the research and development of panels for the detection and diagnosis of traumatic brain injury and other neurodegenerative diseases in acute and chronic settings, we will now have added support from Quanterix to help accelerate the development of important diagnostic tools. We welcome this vote of confidence from our colleagues at Quanterix and look forward to working closely with them.”
“We are excited to expand our collaboration with ImmunArray,” says Kevin Hrusovsky, CEO and executive chairman of Quanterix. “ImmunArray has built an attractive portfolio of brain health biomarkers that nicely complement our existing menu of assays. We are also delighted that they will utilize our Simoa technology to further develop their portfolio for clinical utility.”
Quanterix and ImmunArray are both privately held, funded largely through venture capital investments, and have been grant recipients of the GE-NFL Head Health Challenge to continue their work in improving diagnosis and treatment for mild to moderate traumatic brain injury.
For more information, visit ImmunArray and Quanterix.